Background: The acquisition of intravenous (IV) access in the actively convulsing patient is difficult. This often
Conclusion: Non-IV BDZ, compared to IV BDZ, terminate seizures faster and have a superior efficacy and side effect profile. Higher-quality studies and further evaluation in different age groups are warranted. S tatus epilepticus is the persistence of seizures for a period of 30 minutes or their recurrence without an intervening recovery of consciousness; however, treatment protocols recommend treatment after 5 minutes of continuous seizures. 1 It is an emergency with considerable morbidity and mortality. It is reported to have a fatality rate ranging from 2% up to 30% in certain high-risk populations. [2] [3] [4] Current emergency therapy is satisfactory in majority of cases; however, a subset of cases proves resistant to first-line therapy. 5 The optimal goal for status epilepticus therapy is the attainment of a rapid and sustained cessation of epileptiform discharges with minimal iatrogenic complications. The longer the duration of a seizure the more resistant it becomes to treatment and the worse the outcomes. 6, 7 Previous guidelines and consensus stress the superiority of the intravenous (IV) route citing it as a more reliable and rapid mode of administration. 8 This is not necessarily true in the real world, as the significant delay needed to acquire IV access in a seizing patient can be substantial. Numerous trials have been conducted, but no recent meta-analysis has specifically addressed the effect of the additional time required to acquire IV access on overall treatment outcomes.
We conducted a systematic review and meta-analysis with the aim of providing the best possible answer to the question of whether the use of other, slower-acting modes of delivery that are easier and faster to administer in the real-world setting will result in quicker cessation of seizure activity when compared to IV benzodiazepines (BDZs).
MATERIALS AND METHODS

Data Sources and Search Strategy
The literature was systematically searched for studies that compared the IV administration of a BDZ (of any kind) as treatment for status epilepticus with that of a rectal, buccal, intranasal (IN), or intramuscular (IM; non-IV) BDZ of any kind. We included studies on both pediatric and adult populations in our analysis. In addition, we did not restrict our review to the English language.
Our systematic review included the electronic databases of PubMed and Embase, as well as the Cochrane Database of Systematic Reviews, the database of abstracts of reviews of effects, and the Cochrane central register of controlled trials. All studies published or in press from their inception to July 2016 were included. The majority of our studies were retrieved from PubMed and Embase using a Boolean search strategy (Data Supplement S1, available as supporting information in the online version of record of this paper, which is available at http://onlinelibrary. wiley.com/doi/10.1111/acem.13190/full ).
In addition to the automated searches of these databases, we searched for unpublished studies in ClinicalTrials.gov, Australian New Zealand clinical trials registry (ANZCTR), the EU clinical trials register, and the WHO International Clinical Trials Registry Platform (ICTRP). We looked up the Conference Proceedings Citation Index-Sciences. We then manually went through the reference lists of our articles seeking any additions that met the criteria.
Selection Criteria
Two reviewers (AA and AS) initially evaluated the titles and abstracts of our search results. The remaining articles were evaluated after their full text was retrieved to make sure it compared a non-IV BDZ to an IV BDZ as initial treatment of status epilepticus in children or adults. Only studies that were randomized or quasi-randomized controlled trials (RCTs) were included. Non-IV routes included in our search were IN, IM, per-rectal, and buccal administration. No restriction was made as to the specific BDZ used in the study. Our preset exclusion criteria were then applied; this was to ensure that patient groups are comparable and allow for pooling of our results. We excluded studies that did not compare a non-IV BDZ to an IV BDZ as a first-line treatment for status epilepticus. We also excluded studies conducted on refractory status epilepticus, animal studies, and any study design other than randomized controlled or quasi-randomized controlled. Studies that used BDZs for any indication other than seizure cessation (e.g., sedation or prevention of seizures) were also excluded. In the case of studies evaluating more than one indication or more than one study design, we only included those patients whose indication met our criteria. Any discrepancies between the two reviewers were resolved by discussion.
Quality Assessment and Data Extraction
Further evaluation by the reviewers was performed on the selected articles to assess the risk of bias; this was achieved by the risk-of-bias checklist recommended by the Cochrane collaboration handbook. This seven-item checklist assesses various potential sources of bias in RCTs. We assessed the risk of selection, performance, detection, attrition, reporting, and other bias. It was not used to stratify studies or as an exclusion criterion.
The following variables were then extracted from the analyzed studies using a standardized data collection protocol: author, year of publication, type of study design, definition of SE, age of included patient population, absolute numbers of patients in the IV and the non-IV groups, the specific BDZ used and dosage of drug administered, specific route of non-IV administration, definition and rate of success, and finally, types of complications reported. Data extraction was performed and cross-checked by two authors (AA, AS) and then checked by a third (RB).
Data Analysis
Study inclusion agreement between investigators was evaluated by kappa statistics (SPSS version 16). Pooled odds ratios (ORs) were determined using the MantelHaenszel random-effects model. Heterogeneity within the group was assessed using I 2 statistic, to measure the degree of variation among studies.
An inverse variance random-effects model was used to pool the mean difference for times across studies. Where study data were available, we assessed the mean differences in times between initial assessment and seizure cessation and between drug administration and cessation of seizure activity based on route of administration. The former measure, but not the latter, being influenced by delays caused by IV access acquisition. A random-effects model was used to pool times across the studies.
We calculated pooled respiratory depression using the Mantel-Haenszel random-effects models with 95% confidence intervals (CIs) for respiratory depression. All statistical tests were two-sided. We used Review Manager 5.3 (RevMan; The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) to conduct the analyses.
RESULTS
Search Results and Study Characteristics
The initial literature search of the aforementioned databases yielded a total 2,604 citations, of which 2,526 articles were excluded after screening of titles and abstracts. That left us with 78 potentially relevant articles for full text review. Sixty-seven articles were subsequently excluded after further review. This left us with 11 articles to analyze. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] One study was included in the qualitative analysis only due to lack of data 14 despite author contact for further clarification, yet no response was received. As a result, it was excluded from the quantitative analysis (Figure 1 ). The kappa value for inter-rater reliability for inclusion into the meta-analysis was 0.85, and all differences were resolved by discussion.
The 11 studies included in our analysis have a total of 1,633 patients. Ten are RCTs, and the remainder 16 is an observational longitudinal study but a closer look at the study design shows a portion of patients that presented without IV access were randomized between IV diazepam and IM midazolam. Therefore, we included that randomized subpopulation from their study in our analysis.
Study Characteristics
The included studies characteristics are summarized in (Table 1 ). Ten of our 11 retrieved articles were predominantly pediatric. [9] [10] [11] [12] [13] [14] [15] [16] 18, 19 One exception, 17 accounting for more than half of the analyzed population, had a more balanced age distribution with mean ages of 43 and 44 years in the non-IV and IV groups, respectively (range = 0 to 102 years).
The definition of status epilepticus, as well as the definition of treatment success, varied across studies. The specific BDZ as well as the dosing used in these studies were also heterogeneous but comparable. We encountered a variety of non-IV routes that included IN, IM, and buccal administration. We encountered no article assessing the rectal route in this context.
The quality of the analyzed studies was overall moderate to poor with one high-quality exception. 17 We included all eligible studies in our meta-analysis regardless of the risk of bias. Assessment of the risk of bias showed the risk to be low for selection, attrition, and reporting bias. A high risk of performance and other sources of bias, however, was found ( Figure 2 ).
Treatment Failure Rates
When comparing failure rates (seizure noncessation) of non-IV BDZ to that of IV administered BDZ, there was difference in treatment failure which actually favors non-IV BDZ (OR = 0.72; 95% CI = 0.56-0.92; Figure 3 ).
Visual inspection of the forest plot shows that the results were skewed by one study 17 that accounted for 58.6% of the pooled patient population. It is the largest and highest quality study in the literature. It is also the sole study to have adult population and show a statistically significant benefit one way or the other, and it accounts for our conclusion of favoring non-IV BDZ.
However, after the results of the adults in this study were and only the pediatric population results from its secondary analysis by Welch et al. 20 were added, the results significantly change. The pediatrics subgroup analysis showed no significant difference in efficacy between the two treatments (OR = 1.16; 95% CI = 0.74-1.81; Figure 4 ).
The Effect of IV Access on Interval to
Seizure Cessation Our quantitative analysis shows that IV BDZ, when compared to non-IV BDZ, show a shorter interval between drug administration and seizure cessation (mean difference = 0.74; 95% CI = 0.52-0.95; Figure 5 ). This is not the case when assessing the time to seizure termination from decision to treat, which incorporates the delays imposed by venous access. When these delays are factored in, the advantage of quicker drug action is canceled out by the delay in administration. This resulted in non-IV BDZ having a more rapid net effect (mean difference = -3.41 minutes; 95% CI = -5.13 to -1.69); however, the studies assessing this question were significantly heterogeneous (I 2 = 93%; Figure 6 ). Three studies were not admissible to our analysis, as results could not be pooled. 9, 14, 17 These will be descriptively mentioned: in the study by Silbergleit et al. 17 the interval between drug administration and seizure cessation was shorter in the IV BDZ group (median = 1.6 minutes vs. 3.3 minutes). On the other hand, drug administration from the moment of decision to treat was faster in the non-IV BDZ group (median = 1.2 minutes vs. 4.8 minutes). The end result is a nonsignificant difference in favor of non-IV BDZ.
Mittal et al. 14 in their study also reached a similar conclusion with an overall faster seizure cessation from the point of hospital presentation in the non-IV BDZ group as opposed to the IV BDZ group (mean AE standard deviation = 5.25 AE 0.86 vs. 6.51 AE 1.06). In the RCT by Arya et al. 9 further evidence of nonsuperiority of the IV BDZ was provided by the similar interval to seizure cessation from the moment of drug administration. Both routes achieved that objective in a median of 3 minutes.
Adverse Events
Three studies reported few cases of respiratory depression, however, the definition of respiratory depression varied. 9, 17, 19 Arya et al. 8 reported the cases of respiratory depression that required assisted ventilation. In addition, Silbergleit et al. 16 reported the cases that were endotracheally intubated, whereas Thakker and Shanbag 18 reported one case of respiratory depression based on clinical signs. We found no difference in the incidence of respiratory depression between the two groups (risk difference = 0.00; 95% CI = -0.02 to 0.01). A total 64 of the 760 patients receiving a non-IV BDZ developed respiratory depression, slightly less frequent than that of the IV group (67 out of a total 731).
Other adverse events were not assessed or reported uniformly in all included studies preventing pooling of results. These include hypotension, need for admission, administration-site complications, and thrombophlebitis. 16, 17 No clinically significant difference in complications was found between the two routes with the exception of thrombophlebitis. Table 2 shows reported adverse events through the included studies.
There is evidence that low-quality studies tend to underreport adverse events 21 and our review suggests this. The only high-quality study in our meta-analysis, 17 with 893 of our total 1,633 (54.68%) patients revealed a disproportionately high percentage of respiratory depression events. Of the total 131 risk difference events in the analysis, 127 were from that study alone (97%).
DISCUSSION
This is a meta-analysis of 10 randomized and one quasi-randomized studies with a collective 1,633 patients. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] It is one of the very few to specifically address the value of obtaining IV access in the actively seizing patient. It is also of the very few to incorporate the largest RCT to date by Silbergleit et al. 17 along with its pediatric age group subgroup analysis by Welch et al. 20 The results of our analysis point to the superiority of non-IV BDZs in achieving seizure control in the seizing patient with no readily available IV line. However, the pooled OR of treatment failure using non-IV BDZ as opposed to IV BDZ failed to reach statistical significance in the pediatric population. This is perhaps a function of earlier administration, which is associated with improved response to therapy. 6, 7 The analysis also confirms the safety of non-IV BDZ. We display a similarity in side effects profile with regard to respiratory depression requiring intervention across all studies; however, the majority of cases were reported by a single study. 17 Although they report using a slightly higher than usual dose, we still believe that it suggests that adverse events are underreported or that the other, smaller studies were underpowered to detect this complication, as well as others.
Where non-IV BDZs shine is in their rapidity of administration. This had important implications on overall speed of seizure termination that was displayed in our analysis. Despite IV BDZ terminating seizures more quickly once administered, the delay in administration was significant enough to offset this advantage.
This obviously does not apply to the patient with an installed IV cannula. This provides us with our conclusion that in the actively seizing patient with no IV access, the best action is to administer a non-IV BDZ while acquiring IV access for subsequent doses if needed. As with regard to which non-IV route is best, or which agent is superior, no clear answer is provided by the literature.
One randomized trial by Lissauer et al. 22 compared three routes (buccal, IN, and IV) of lorazepam for acute seizure treatment in Malawian children. However, this study was not included in our systematic review and meta-analysis as it was terminated early for harm as the anticipated difference was smaller than the difference between the groups.
LIMITATIONS AND IMPLICATIONS FOR FURTHER RESEARCH
We found a striking lack of high-quality studies evaluating this aspect of status epilepticus therapy. The majority of studies we retrieved were either underpowered or methodologically flawed with a high risk of performance and detection bias. On the other hand, some of the included studies have a questionable risk of selection bias, although it was avoidable. In addition, most of the included studies have a small number of cases that underestimate the real effect and underreport the adverse events as well. Our study also is limited by the lack of literature assessing the different modes of administration. This resulted in us collectively analyzing non-IV BDZ as one group. These are different agents with different efficacies given through different routes each with its own pharmacokinetics. This limits our ability to draw a conclusion as to which specific BDZ through which specific route is ideal, but opens up a deficiency that warrants further research.
In addition, the IV BDZs were different among the included studies as some studies used diazepam whereas others used lorazepam with variable doses as well. However, these two drugs showed similar efficacy in terminating seizures and side effects if given intravenously. 23 A meta-analysis is a function of the quality of the studies they incorporate and this is probably its main shortcoming. We at least hope that it highlights the need for further high-quality research to provide solid evidence-based guidance for our clinical judgment and decision making. We also hope it provokes a discussion as to why current practice does not reflect the currently available best clinical evidence.
CONCLUSIONS
In patients without intravenous access, nonintravenous benzodiazepines, especially intramuscular and intranasal, compared to intravenous benzodiazepine, terminate seizures faster and have a superior efficacy with similar side effect profile. However, pediatric subgroup analysis showed similar efficacy in seizure cessation. As only one study was of high quality and included adult patients, higher-quality studies and further evaluation in different age groups are warranted.
